The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
The Serum Institute of India and Bharat Biotech are in talks with the Mexican government for manufacturing vaccines in a deal that will help the two Indian pharmaceutical companies expand their presence in Mexico and the Latin American market. 6 June 2023
As the final sessions of the 2023 congress of the American Society of Clinical Oncology (ASCO) draw to a close, attendees will reflect on a number of significant presentations, from both smaller biotechs and large drugmakers. 6 June 2023
Day One Biopharmaceuticals shares leapt 33.8% to $18.19 in pre-market trading on Monday, after the company announced overall response rate of 67% and clinical benefit rate of 93% in 69 heavily pre-treated RANO-HGG evaluable patients in pediatric low-grade glioma trial. 6 June 2023
Portuguese neuroscience specialist BIAL has announced positive results from the Phase III EPSILON trial of its innovative Parkinson’s disease therapy Ongentys (opicapone). 6 June 2023
US biotech major Gilead Sciences’ recent investments into oncology - including its $11.9 billion acquisition of Kite Pharma in 2017 - have made the company one of the major players in the oncology space. 6 June 2023
A post-marketing Phase IV trial to assess the efficacy and safety of Andexxa (andexanet alfa) in patients on oral FXa-inhibitor treatment including apixaban and rivaroxaban experiencing an intracranial hemorrhage, is to be stopped early. 5 June 2023
Along with the big pharma players showing off the potential of their cancer drugs at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO), biotech companies have been making their presence felt, too. 5 June 2023
Belgium’s largest pharma company UCB today revealed that its developmental treatment for adults with hidradenitis suppurativa (HS) has been granted Promising Innovative Medicine (PIM) designation in the UK by the Medicines and Healthcare Products Regulatory Agency (MHRA). 5 June 2023
GLP1 receptor agonists (GLP1RA) are known as diabetes treatments, but recently they have also doubled as the new generation drugs for overweight/obesity. 5 June 2023
Gilead Sciences subsidiary Kite prides itself on being a leader in the development of cell therapies, a claim backed by its pioneering work with Yescarta (axicabtagene ciloleucel). 5 June 2023
Data presented at the American Society of Clinical Oncology (ASCO) reinforce enthusiasm for a new approach being developed by companies including Elevation Oncology. 5 June 2023
Both AstraZeneca and Merck & Co have presented data at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO) that reflects the ability of their drugs to boost survival in lung cancer. 5 June 2023
French privately held pharma major Servier has presented results from the pivotal Phase III INDIGO clinical trial investigating vorasidenib, showing efficacy in the treatment of low-grade glioma, a difficult to treat form of brain cancer. 5 June 2023
More than three dozen state-level enforcers reached a $102.5 million deal with Indivior to resolve claims that the drugmaker monopolized the market for the opioid addiction treatment Suboxone (buprenorphine) ahead of a looming September trial. 5 June 2023
A targeted drug combination for patients with a type of ovarian cancer could be nearly twice as effective as the next best treatment, according to interim results from a Phase II study presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. 5 June 2023
In an oral presentation at the annual meeting of the American Society of Clinical Oncology (ASCO), Eli Lilly revealed new data for its CD4 and CD6 blocker Verzenio (abemaciclib). 5 June 2023
On June 1, a new unitary patent system came into effect in Europe. The system allows inventions to be protected by a single unitary patent in 17 European Union countries. 5 June 2023
Danish diabetes care giant Novo Nordisk has entered into exclusive negotiations for a controlling stake in France-based Biocorp, which would be followed by a mandatory simplified tender offer on all remaining outstanding shares in Biocorp. 5 June 2023